期刊文献+

基于多准则决策模型评价芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血的效益-风险

Effectiveness-risk Evaluation of Qili Qiangxin Capsules and Iron in the Treatment of Heart Failure with Iron-deficiency Anemia Based on Multi-criteria Models for Decision-making
下载PDF
导出
摘要 目的:基于多准则决策模型评价芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血的效益-风险。方法:将80例心力衰竭合并缺铁性贫血患者按随机数字表法分为对照组和研究组各40例。对照组在常规治疗基础上予芪苈强心胶囊,研究组在对照组治疗基础上联合铁剂治疗,持续治疗3个月。比较两组患者治疗前后6分钟步行试验的步行距离(the six minutes walking distance,6MWD)、左心室收缩末期内径(left ventricular end systolic diameter,LVESD)、左心室舒张末期内径(left ventricular enddiastolic dimension,LVEDD)、左心室射血分数(left ventricular ejection fraction,LVEF),血清内N末端B型利尿钠肽原(N-terminal B-type prodiuretic natriuretic peptide,NT-proBNP)和超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)表达水平。建立芪苈强心胶囊联合铁剂治疗心力衰竭合并缺铁性贫血多准则决策分析模型。比较两组效益指标和风险指标效应值,并评价模型的灵敏度。结果:治疗后,研究组患者LVESD、LVEDD及血清NT-proBNP、hs-CRP水平均低于对照组(P<0.05),而6MWD、LVEF高于对照组(P<0.05);研究组总有效率[90.00%(36/40)]高于对照组[77.50%(31/40)](P<0.05);研究组不良反应发生率[10.00%(4/40)]低于对照组[30.00%(12/40)](P<0.05);研究组和对照组的效益值分别为83和47,风险值分别为26和25,效益-风险总值分别为55和36,研究组的效益-风险总值最高;无论效益-风险的相对权重如何改变,模型评价结果均保持不变。结论:芪苈强心胶囊联合铁剂能有效改善心力衰竭合并缺铁性贫血患者的预后,降低患者不良反应发生率。 Objective:To assess the effectiveness-risk of Qili Qiangxin capsules combined with iron in the treatment of heart failure and iron-deficiency anemia based on multi-criteria models for decision-making.Methods:Eighty patients were allocated to the control group and the study group according to random number table method with 40 cases in each group.The control group took Qili Qiangxin capsules on the foundation of conventional therapy,iron was administered to the study group based on the therapy of the control group,and both groups were treated for three months consecutively.To compare 6MWD,LVESD,LVEDD,LVEF,the expressions of NT-proBNP and hs-CRP before and after the treatment between the two groups.To establish the multi-criteria models for decision-making in the treatment of heart failure and iron-deficiency anemia with Qili Qiangxin capsules and iron.To compare the effect values of benefit and risk indicator between both groups,and to evaluate the sensitivity of the model.Results:After the treatment,LVESD,LVEDD,the levels of NT-proBNP and hs-CRP in the study group were lower than these of the control group(P<0.05),while 6MWD and LVEF higher than these in the control group(P<0.05);total effective rate of the study group was[90.00%(36/40)],higher than[77.50%(31/40)]of the control group(P<0.05);the incidence of adverse reaction of the study group was[10.00%(4/40)],lower than[30.00%(12/40)]of the control group(P<0.05);the effect values of the study group and the control group were 83 and 47 respectively,risk values were 26 and 25 respectively,total values of effectiveness-risk were 55 and 36 respectively,total value of effectiveness-risk was the highest in the study group;the results of the model evaluation remained the same regardless of the change in the the relative weighting of effectiveness-risks.Conclusion:Qili Qiangxin capsules combined with iron could effectively improve the prognosis of heart failure and iron-deficiency anemia,and reduce the incidence of adverse reaction.
作者 孙小燕 杨雷 王蕾 屈伶玉 赵玉清 狄巨岚 刘学英 柴志强 吴泽阳 SUN Xiaoyan;YANG Lei;WANG Lei;QU Lingyu;ZHAO Yuqing;DI Julan;LIU Xueying;CHAI Zhiqiang;WU Zeyang(Zhangjiakou City First Hospital,Zhangjiakou 075000,China)
出处 《西部中医药》 2024年第10期109-114,共6页 Western Journal of Traditional Chinese Medicine
基金 张家口市重点研发计划项目(2121151D)。
关键词 心力衰竭 缺铁性贫血 芪苈强心胶囊 多准则决策分析 效益 风险 heart failure iron-deficiency anemia Qili Qiangxin capsules multi-criteria decision-making analysis effectiveness risk
  • 引文网络
  • 相关文献

参考文献13

二级参考文献148

共引文献1137

;
使用帮助 返回顶部